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ABSTRACT 
The aim of the present research work is to explore the application of mixed solvency concept to formulate and develop a fast 
dissolving oral film of furosemide with improved drug loading. In the present study, poorly soluble drug, furosemide was tried to be 
solubilized by employing the combination of physiologically compatible water-soluble additives (solubilizers) to formulate its fast 
dissolving formulations. For the development of fast dissolving oral film, firstly, different film forming polymers were tested for 
their film properties. The second fast dissolving layer was also formed and optimized. Solubility studies were conducted to select 
water-soluble additives for formulation of fast dissolving drug layer. Keeping the total concentration less than 40 % w/v of mixed 
blends, different aqueous blends were prepared employing solubilizers from among sodium benzoate, sodium acetate, sodium 
citrate, urea, niacinamide, glycerin, propylene glycol, polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600, and 
PVP K 30. Maximum solubility of furosemide was found in blends- F5 (10% sodium caprylate +2.5%sodium benzoate+ 2.5% 
niacinamide) and in blend F7 (10% sodium caprylate +2.5%sodium benzoate +2.5% sodium citrate + 2.5% niacinamide). Prepared 
films were evaluated for drug content, thickness, folding endurance, tensile strength and hydration ratio.  
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INTRODUCTION 
Oral drug delivery is the most widely acceptable drug 
delivery system as it provides numerous advantages when 
compared to other drug delivery systems. But due to some 
limitations like lesser bioavailability of drug, longer onset 
time and dysphagia patients, manufacturers bend towards 
parenteral and liquid orals. Whereas liquid orals having the 
problem associated with accurate dosing and also painful 
for parenteral drug administration, which creates patient 
incompliance. There are three important factors for any 
drug product viz bioavailability, quicker action (if 
required) and patient compliance. So, each company wants 
to formulate the products which fulfils these three factors 
according to the patient’s need to increase their market 
profile [1]. To provide maximum concentration at the site of 
action of drug and achieve therapeutic level and to 
maintain it is main aim of any drug delivery system.  
Fast dissolving oral film (FDF) 
This novel drug delivery system was introduced as a 
substitute for conventional oral dosage forms for patients 
who cannot swallow medicines easily, bed-prone patients, 
geriatric patients and pediatric patients. Orally 
disintegrating tablets are present in the market which 
gives disintegrating time of one to two minutes. Mouth 
dissolving films were then introduced which significantly 
marked an upgradation in the oral disintegrating drug 
delivery system. The various avenues explored for rapid 
drug releasing product, mouth dissolving film method is 
gaining much attention. [2] 
Recently, the regulatory authorities have enlarged the 
variety of “oro mucosal preparations” by buccal films and 
oro dispersible films. The United States Food and Drug 
Administration (USFDA) use the term ‘soluble film’ for 
mouth dissolving films. The European Pharmacopoeia 
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(Ph.Eur.) monograph on oro mucosal preparations was 
updated in its 7.4 edition, including ‘mucoadhesive 
preparation’ and ‘fast dissolving film’. Mouth dissolving 
films are described in the monograph as rapidly dispersing 
single or multilayer sheets of suitable material. [3] 
Mouth dissolving films contain active molecules which are 
dissolved or dispersed in the film, the film is placed on a 
tongue of patient where it gets disintegrated and dissolves 
to release the drug for absorption. The problem of drug 
administration of certain groups of patients like 
paediatrics, geriatric, bedridden, nauseous or 
noncompliant patients, and scientists developed new 
dosage alternatives from oral route to keep these patients’ 
group in mind and mouth-dissolving film is one of the 
alternative dosage forms of oral route.  
Drug release mechanism of FDF 
The mouth dissolving oral film is a very thin film placed on 
tongue, gets instantly wetted by saliva, disintegrates and 
dissolves rapidly to release drug. This released drug gets 
absorbed directly in to the systemic circulation by oral 
mucosa. Oral mucosal drug delivery is a potential site for 
drug administration. It provides rapid onset of action, 
enhanced bioavailability of drug and by passes pre-
systemic elimination within GI tract. Oral mucosa is highly 
permeable and rich in blood supply, so the drug is directly 
absorbed into the blood circulation.                                        
General composition of FDF 4 
Table 1: The fast dissolving film consists of general 
ingredients in the following quantities 
S.No. Ingredients list Quantity (w/w) 
1. Drug              1-25%  
2. Water soluble polymer             40-50%   
3. Plasticizer              0-20%  
4. Saliva stimulating agent              2-6%  
5.  Sweetening agent              3-6% 
6. Flavouring agent,               q.s.  
7. Surfactant               q.s. 
8. Colours               q.s. 
9. Filler               q.s. 
 
Method of preparation of FDF 5  
There are five methods for the preparation of FDF: - 
 Solvent casting   
 Semisolid casting  
 Hot melt extrusion  
 Solid dispersion extrusion  
 Rolling method  
Solvent casting method: - In suitable solvent, water-
soluble polymers are dissolved and in another suitable 
solvent, the drug along with other excipients is dissolved, 
then both solutions are mixed well and casted into the petri 
plate and kept for drying.  
Mixed Solvency Concept 
Maheshwari [6] proposed the concept of mixed-solvency 
concept and proved that all substances whether liquids, 
solids or gases may enhance the solubility of poorly-soluble 
drugs. He has carried out solubility studies on poorly-water 
soluble drug, salicylic acid (as model drug). Solubility 
studies were carried in the solutions containing 
hydrotropic agents (urea and sodium citrate), cosolvents 
(glycerin, propylene glycol, PEG 300 and PEG 400) and 
water-soluble solids (PEG 4000 and PEG 6000) individually 
as well as in 10 randomly prepared blends keeping total 
concentration constant i.e. 40%. Results showed that seven 
out of ten blends produced synergistic effect on solubility 
enhancement. 
Several studies [7-29] have been conducted on various poorly 
soluble drugs using mixed solvency concept. 
 
 
 
MATERIALS AND METHOD 
Materials 
Furosemide drug was obtained as a gift sample from IPCA 
Laboratories, Pithumpur. Other chemicals used were of 
analytical grade. Demineralized water was used in the 
study. 
 
Method 
Preparation of aqueous solutions of solubilizers  
For the preparation of different blends of solubilizers (% 
w/v), sodium caprylate, niacinamide, sodium citrate, 
caffeine, PVP k 30, propylene glycol, PEG 200, PEG 400, PEG 
600, glycerin etc. were weighed/ measured and taken in a 
volumetric flask and about 50 ml of DM water was added in 
this flask and was shaken to achieve complete dissolution of 
       Polymer dissolved in solvent + Drug and all other excipient dissolved in suitable solvent to form solution 
 solutions are mixed well  (rapid stirring) 
   Homogenous solution is then spread (on flat surface) & keep for Drying  
Film formed 
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solubilizers. Then, volume was made up to 100 ml by DM 
water. Total solute concentration was varied up to 40% w/v 
concentration and the % solubility of drug (furosemide) was 
calculated.  
Solubility studies: 
Solubility studies in different aqueous systems of 
solubilizers were carried out by equilibrium solubility 
method. 
According to this method, 5 ml of respective medium was 
taken in a vial and excess amount of drug furosemide was 
added in above vial, kept it closed by rubber cap with 
aluminium seal, and was placed on a mechanical shaker at 
room temperature for 12 hours, and solution was allowed to 
equilibrate for 24 hours undisturbed. Then, the solution was 
filtered through filter paper. The filtrate was appropriately 
diluted with the respective aqueous medium and the 
absorbance of the solution was measured at 333 nm on a 
double beam UV/Visible spectrophotometer (Shimadzu 
1700) against respective reagent blanks. The percent 
solubility was calculated using calibration curves.
  
 
Solubility of furosemide in different medium  
Table 2: Drug solubility in different medium 
S. No. Solvent Solubility of furosemide (mg/ml) Solubility (% w/v)  
1 D.M. water            0.0792 0.0079 
2 0.1 N HCl  0.0570 0.0057 
3                                Buffer (pH 6.8) 1.6500 0.1650 
4 A. 15% Propylene glycol 5.5470 0.5547 
5 B. 15% Glycerin  14.6600 1.4660 
 
Table 3: Solubility of drug in aqueous solutions containing solid solubilizers 
S.No. Blend Aqueous blend of 
solubilizers 
Ratio of solubilizer 
concentration (% w/v) 
Solubility of 
furosemide (mg/ml) 
Solubility (% 
w/v) 
1 C Sodium caprylate 20% 85.00 8.500 
2 D Sodium benzoate 20% 62.70 6.270 
 
Table 4: Solubility of drug in aqueous solutions containing combinations of solubilizers 
S.No. Blend Blends composition (w/v)  Solubility of furosemide (mg/ml) Solubility 
(% w/v) 
 
6 E 20%SC+5%SB+5%NM     125.68 12.568 
7 F 20%SC+10%SA+5%PVPK30  53.01 5.301 
8 G 20%SC+10%SB+10%NM  121.51 12.151 
9 H      10%SC+2.5%SB+2.5%NM 115.24 11.524 
10 I 10%SC+10%SB+10%NM  57.21 5.721 
11 J       20%SC+10%SB+5%NM   83.85 8.385 
12   K 20%SC+5%SA+5%SCI 56.36 5.636 
13 L      10%SC+10%SB+10%SA 36.17 3.617 
14 M      10%SC+2.5%SB+2.5%NM+5% SCI 131.60 13.160 
15 N      10%SC+2.5%SB+2.5%NM+2.5% SCI 124.36 12.436 
16 O      20%SC+5%SB+5%NM+5% SA 91.86 9.186 
17 P       20%SC+5%SB+5%NM+10% SA Because of excess solubility, semi solid mass was 
produced and it could not be filtered to determine 
the solubility 
-- 
18 Q      10%SC+2.5%SB+2.5%NM+10% SCI Because of excess solubility, semi solid mass was 
produced and it could not be filtered to determine 
the solubility 
-- 
19 
R      20%SC+20%SB+10%NM  
Because of excess solubility, semi solid mass was 
produced and it could not be filtered to determine 
the solubility 
--- 
 
20 
 
S       20%SC+5%SB+5%SA 
Because of excess solubility, semi solid mass was 
produced and it could not be filtered to determine 
the solubility 
--- 
Here- SC-Sodium caprylate, NM-Niacinamide, SB-Sodium benzoate, SCI-sodium citrate, SA-Sodium acetate 
 
Selection of polymers  
For selection of water-soluble film forming polymers, films 
of different polymers were prepared and their film 
properties were evaluated. As the important function of 
polymer was to provide mechanical strength and quick 
disintegration to the film, its selection was done taking 
physical strength and disintegration as the most important 
optimization parameters of the film. 
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Procedure: 
For preparation of polymer films, 8.5 ml of blend 
containing 15% v/v glycerin (as plasticizer) was taken in a 
vial. Polymer (1.5 gm) was added and made up to 10 ml 
with blend, preparation was stirred properly and placed 
undisturbed for 5-6 hrs. The film of resulting polymer 
solution was casted in petri plate and was dried at 40ºC in 
hot air oven for 24 hours and then wrapped in aluminium 
foil and stored. The prepared films were evaluated for their 
film properties. 
Evaluation of casted polymeric film  
a) Disintegration time 
Disintegration was tested by taking 25 ml of phosphate 
buffer (pH 6.8) in a Petri dish and a film was placed in it. 
Swirling of the buffer was done manually in every 10 
seconds. Time required to completely break and disperse 
the film was noted as the disintegration time.  
b) Folding endurance  
Folding endurance was determined by repeatedly folding 
the film at the same position until it breaks. The number of 
times the films can be folded without breaking is termed as 
the folding endurance value.  
 c) Thickness  
The thickness of film was determined by the use of 
micrometre (Digimatic micrometre, Mitutoyo, Tokyo, 
Japan) at five locations (centre and four corners) and mean 
thickness was calculated. 
 
Table 5: Evaluation of film properties 
S.no.  Polymer used Appearance of film  Disintegration time (sec) Thickness (mm) 
1. 
 
HPMC E-5  Transparent, smooth, thin, non-tacky,  
easily removed from Petri plate 
45 
 
0.09 
 
2. 
 
HPMC E-50  Transparent, smooth, thick, non-tacky,  
easily removed from Petri plate 
100 
 
0.23  
 
3. PVP K30   Semi-transparent, smooth, sticky and tacky  ---  --- 
4. Gelatine  Gummy film, transparent, sticky and tacky  ---  --- 
5. Starch  Whitish translucent, thick, brittle film   115  0.34 
6. CMC  Whitish translucent, thick, sticky ---  --- 
 
Optimization of concentration of polymer 
Five batches of different selected polymer (HPMC E-5) concentrations were prepared, casted and their film properties were 
studied. 
Table 6: Properties of different concentrations of HPMC E-5 
S.No. Selection factor  
 
10% w/v  
HPMC E-5 
12.5% w/v 
HPMC E-5 
15% w/v 
HPMC E-5 
17.5% w/v 
HPMC E-5 
20% w/v  
HPMC E-5 
1.  
 
Viscosity of 
polymeric 
preparation 
Less viscous Less viscous Viscous Viscous Viscous 
2 Pourability Easily pourable Easily pourable Pourable Pourable Difficult to pour  
3. Appearance of film 
and folding 
parameter 
Transparent but 
easily break on 
folding 
Transparent, 
little folding 
capacity  
Transparent, 
with high 
folding capacity 
Transparent 
with high folding 
capacity 
Transparent but 
easily breakable 
4. Uniformity of film  Uniform Uniform Uniform Uniform  Non-uniform 
5. Thickness  Thin 0.10 mm Thin 0.12mm Thin 0.09mm Thin 0.11 mm Thick  0.14 mm 
 
Selection of plasticizer  
The effect of glycerine, propylene glycol, polyethylene glycol as plasticizer was studied. Five batches of HPMC E-5 films were 
prepared with respective plasticizers used in concentration of 15% v/v and properties of casted films were evaluated.   
Table 7: Effect of different plasticizers in polymeric casted film 
S.No. Polymer  
(15%w/v)  
Plasticizer  
(15%v/v)  
Appearance of film  Thickness  
(mm)  
Folding 
endurance  
Disintegration 
time (sec)  
1. HPMC E-5  
 
PG  Thin, smooth, transparent, 
uniform  
0.08 114  56 
 
2. HPMC E-5  
 
Glycerine  Transparent, thickness is greater 
than first film, less smooth 
compared to first batch 
0.07 157 40 
 
3. HPMC E-5 PEG 200 Smooth, transparent, thickness is 
greater than first film  
0.11 126 44 
4. HPMC E-5  PEG 400 Non-uniform, thickness is greater, 
transparent  
0.13 149 57 
5. HPMC E-5  
 
PEG 600 Thickness is greater than first 
three batches, transparent  
0.17 145 67 
Here-HPMC-hydroxy propyl methyl cellulose, PEG -poly ethylene glycol, PG-propylene glycol.  
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Optimization of plasticizer concentration  
Five batches of HPMC E-5 with different concentration range 5%-25% of selected plasticizer (Glycerine) were prepared and 
their film properties were studied. 
Table 8: Effect of different concentrations of selected plasticizers in properties of polymeric film 
S.No. Polymer 
(15%w/v)  
Glycerine 
Concentration 
(v/v) 
Appearance of film  Thickness  
(mm)  
Folding 
endurance  
 
Disintegration 
time (sec)  
 
1. HPMC E-5  5%  Hard and brittle  0.12 23 43 
2. HPMC E-5  10%  Hard, uniform, transparent  0.10  61 49 
3. HPMC E-5  15%  Soft, smooth, uniform, transparent  0.07 177 39 
4. HPMC E-5  20%  Soft, sticky, transparent  0.15 145 44 
5. HPMC E-5  25%  Soft, very sticky  0.17 133  50 
 HPMC- hydroxypropyl methyl cellulose.  
Selection of super disintegrants  
Solutions of four different polymeric formulations of HPMC E-5 (15% w/v) were prepared with (15% v/v) glycerin and in 
each of this solution respective super disintegrant (0.3%w/v) was added and films were casted in Petri plates, after proper 
drying at 40°C for 24 hours then films were wrapped in aluminium foil with sealing plastic bags, stored and their film 
properties were studied.  
Table 9: Effect of super disintegrant on the properties of polymeric film  
S.No. Polymer  
(15%w/v) 
Plasticizer 
concentration 
(15% v/v) 
Super disintegrant Thickness 
(mm)  
Disintegration 
time (sec) 
1. HPMC E-5  Glycerine Croscarmellose sodium (ac-di-sol)  0.14 45 
2. HPMC E-5  Glycerine Crosspovidone 0.06 37 
3. HPMC E-5  Glycerine Microcrystalline cellulose (avicel) 0.15 64 
4. HPMC E-5  Glycerine Sodium starch glycolate  0.17 53 
 
Optimization of super disintegrant concentration  
Solutions of four different polymeric formulations of HPMC E-5 (15% w/v) were prepared with (15% v/v) glycerine and in 
each of this solution cross povidone in different concentration range 0.3%-0.6% w/v were added in preparation and films 
were casted in Petri plate, after proper drying at 40°C for 24 hours then film were wrapped in aluminium foil with sealing 
plastic bags, stored and their film properties were studied.  
Table 10: Effect of different concentrations of cross povidone on the properties of polymeric films 
S.No. Polymer  
(15%w/v)  
Plasticizer conc. 
(15% v/v) 
Crosspovidone  
(% w/v)  
Thickness 
(mm)  
Folding 
endurance  
Disintegration 
time (sec)  
1. HPMC E-5  Glycerine 0.3%  0.09 166 37 
2. HPMC E-5  Glycerine 0.4%  0.06 173 29 
3. HPMC E-5  Glycerine 0.5%  0.12 164 34 
4. HPMC E-5  Glycerine 0.6%   0.11 170 38 
 
Formulation of FDF of furosemide  
According to the preliminary studies and studies of selection of excipients, for the preparation and optimization of fast 
dissolving film layer, 8 batches were designed and fast dissolving films of different 8 formulae (table 31) were prepared (on 
the basis of less individual concentration of solubilizers and greater solubility enhancement of drug.)  
Table 11: Composition of blends used for formulation development 
S.No. Blend 
name 
                                                COMPOSITION 
Sodium caprylate 
(w/v) 
Sodium 
benzoate (w/v) 
Niacinamide (w/v) Sodium 
citrate (w/v) 
Sodium 
acetate (w/v) 
1 B1 20% 20% 10% --- --- 
2 B2 20% 5% --- --- 5% 
3 B3 20% 10% 5% --- --- 
4 B4 10% 10% 10% --- --- 
5 B5 10% 2.5% 2.5% 2.5% --- 
6 B6 10% 2.5% 2.5% 5% --- 
7 B7 10% 2.5% 2.5% ---- --- 
8 B8 20% 5% 5% ---- 5% 
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Table 12: Composition of formulation of fast dissolving films 
S.No. Batch 
code 
Drug furosemide 
(mg) 
Blends Polymer 
HPMC E-5 (%w/v) 
Plasticizer 
(% v/v) 
Super disintegrants 
(% w/v) 
1. F1 500 B1 15% 15% 0.4% 
2. F2 500 B2 15% 15% 0.4% 
3. F3 500 B3 15% 15% 0.4% 
4. F4 500 B4 15% 15% 0.4% 
5. F5 500 B5 15% 15% 0.4% 
6. F6 500 B6 15% 15% 0.4% 
7. F7 500 B7 15% 15% 0.4% 
8. F8 500 B8 15% 15% 0.4% 
  
Method of preparation of FDF of furosemide  
500 mg furosemide was accurately weighed and dissolved 
in 8.5ml of respective solubilizer blend containing 15% v/v 
glycerine (as plasticizer). fourty mg crospovidone (as super 
disintegrant) and 1.5 gm of HPMC E-5 (as film forming 
polymer) were added and made up to 10 ml with blend. 
Preparation was properly mixed in blend and placed 
undisturbed for 5-6 hour. Then calculated volume of 
polymeric preparation were uniformly spread in Petri plate 
and dried in oven at temperature 40°C for 24 hrs. After 
proper drying, films were cut into desired calculated 
dimension i.e. 2.0×2.0 cm² in which 20 mg of furosemide 
was present. At last it was wrapped in an aluminium foil 
with sealing plastic bag and stored for further evaluations 
of film.    
Dose calculation of drug: -  
Outer diameter of Petri plate = 5.5 cm  
Inner diameter of Petri plate = 5.2 cm  
Inner radius of Petri plate = 5.2/2 cm = 2.6 cm 
 Inner area of Petri plate = area of circle= πr² 
                                                                = 3.14× (2.6) ²      
                                                                = 21.2264 cm² 
10 ml of polymeric preparation contains 500mg of drug.  
Therefore 2 ml of polymeric preparation contains 100 mg 
of drug. 
This 2 ml polymeric preparation was spread over 21.2264 
cm² area of Petri plate.  
Therefore, 100 mg of drug is present in 21.2264 cm² area 
of Petri plate.  
So, 20 mg present in…. = (21.2264 cm2 / 100 mg) ×20 mg       
                                       = 4.24528 cm2 area  
 Area of circle = area of square = a² (a= length of side of 
square) 
                             4.24528 cm² = a²  
                                                a = √4.24528 cm²  
                                                a = 2.06 cm  
By this calculation 20 mg dose of drug present in 2.0×2.0 
cm² area of film.   
Evaluation studies of fabricated FDF 
a) In vitro dissolution rate study  
Films containing 20 mg of furosemide were used in the in 
vitro dissolution study. Dissolution studies were conducted 
in USP II apparatus (paddle type) at 50 rpm, using 900 ml 
of 0.1 N HCl and 300 ml of simulated saliva fluid (2.38 gm 
Na2HPO4, 0.19 gm KH2PO4, and 8.00 gm NaCl per litre of 
distilled water adjusted with phosphoric acid to pH 6.8) as 
dissolution media. The temperature was maintained at 
37±0.5˚ C. Ten ml samples were withdrawn at regular 
intervals and analyzed spectrophotometrically (Shimadzu 
A-160) at 333 nm after appropriate dilution with 0.1 N HCl 
and simulated saliva fluid respectively. Absorbances were 
noted against respective reagent blanks (placebo). An 
equal amount of fresh dissolution media was replaced 
immediately after each withdrawal of sample.   
b) % Drug content determination  
It was determined by taking one film theoretically 
equivalent to 20mg of drug and transferred in 1000 ml 
volumetric flask and approximately 400 ml of DM water 
was added to it. Flask was shaken for 15 minutes and 
volume was made up to the mark with DM water. The 
resulting solution was filtered and analyzed 
spectrophotometrically at 333 nm and drug content was 
determined.  
% drug content= (practical value/ theoretical value) × 100 
c) Surface pH  
Film was taken and placed in a Petri plate containing 5 ml 
of water. After wetting of the film, the surface pH of the film 
was checked by using pH electrode.  
d) Thickness  
The thickness of film was determined by the use of 
micrometre (Digimatic micrometre, Mitutoyo, Tokyo, 
Japan) at five locations (centre and four corners) and mean 
thickness was calculated. 
 
Table 13: Evaluation of formulated film batches 
S.No.  Batch code  Mean thickness (mm) Folding endurance  Disintegration time (sec) 
1. F1 0.14 153 37 
2. F2 0.19 169 34 
3. F3 0.09 157 37 
4. F4 0.11 152 45 
5. F5 0.04 175 26 
6. F6 0.12 142 36 
7. F7 0.03 178 27 
8. F8 0.13 155 30 
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In vitro dissolution rate study-Films containing 20 mg of 
furosemide were used in the in vitro dissolution study. 
Dissolution studies were conducted in USP II apparatus 
(paddle type) at 50 rpm, using 900 ml of 0.1 N HCl and 300 
ml of simulated saliva fluid (2.38 gm Na2HPO4, 0.19 gm 
KH2PO4, and 8.00 gm NaCl per litre of distilled water 
adjusted with phosphoric acid to pH 6.8) as dissolution 
media. The temperature was maintained at 37±0.5˚ C. Ten 
ml samples were withdrawn at regular intervals and 
analysed spectrophotometrically (Simadzu A-160) at 333 
nm after appropriate dilution with 0.1 N HCl and simulated 
saliva fluid respectively. Absorbance was noted against 
respective reagent blanks (placebo). An equal amount of 
fresh dissolution media was replaced immediately after 
each withdrawal of sample. 
 
 
Figure 1: Graphical representation of % cumulative drug release v/s time plot in phosphate buffer of pH 6.8 
  
 
Figure 2: Graphical representation of % cumulative drug release v/s time plot in 0.1 N HCl  
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Figure 3: In-vitro dissolution profile of optimized batch FD5 
 
 
Figure 4: In-vitro dissolution profile of optimized batch FD7 
Stability study of optimized batch FD5 and FD7 
Stability study of optimized film formulation was carried out for two months at room temperature and refrigerated 
temperature.  
Table 14: Stability studies of final optimized batch FD5 
Stability condition  Sampling interval (days)  Evaluation parameters for Batch FD5  
% Drug content  Surface pH  Thickness (mm) 
 
 
 
 
 
Room temperature 
0 99.78 6.80 0.01 
7 99.43 6.80 0.01 
14 98.73 6.82 0.01 
21 98.38 6.83 0.01 
28 98.04 6.85 0.01 
35 97.69 6.87 0.01 
42 97.34 6.88 0.01 
49 96.64 6.88 0.01 
56 96.30 6.90 0.01 
63 95.95 6.91 0.01 
70 95.56 6.93 0.01 
 
 
 
 
 
Refrigerated 
temperature 
0 99.64 6.80 0.01 
7 98.32 6.80 0.01 
14 98.38 6.80 0.01 
21 97.69 6.81 0.01 
28 97.34 6.82 0.01 
35 96.99 6.85 0.01 
42 96.64 6.88 0.01 
45 95.95 6.89 0.01 
56 95.56 6.89 0.01 
63 94.90 6.90 0.01 
70 94.56 6.91 0.01 
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Table 15: Stability studies of final optimized batch FD7 
Stability condition  Sampling interval(days) Evaluation parameters for Batch FD7 
% Drug content  Surface pH  Thickness (mm)  
 
 
 
 
 
 
Room temperature 
0 99.82 6.80 0.01 
7 99.08 6.80 0.01 
14 98.46 6.81 0.01 
21 98.32 6.83 0.01 
28 98.04 6.83 0.01 
35 97.63 6.84 0.01 
42 96.99 6.85 0.01 
49 96.64 6.88 0.01 
56 95.99 6.90 0.01 
63 95.25 6.91 0.01 
70 94.90 6.92 0.01 
 
 
 
 
Refrigerated 
temperature 
0 99.43 6.80 0.01 
7 98.73 6.80 0.01 
14 98.38 6.81 0.01 
21 98.21 6.83 0.01 
28 97.63 6.85 0.01 
35 96.69 6.87 0.01 
42 96.32 6.88 0.01 
45 96.28 6.88 0.01 
56 95.76 6.90 0.01 
63 95.56 6.93 0.01 
70 94.54 6.96 0.01 
 
RESULTS AND DISCUSSION 
For the selection of solubilizers for increasing the solubility 
of drug (furosemide), solubility studies were conducted at 
room temperature in various solutions containing 
individual solubilizer or in combination of solubilizers 
blend. The solubility of furosemide was increased up to 
11.52 % (w/v) in solubilizer in Blend F5 (10% sodium 
caprylate +2.5%sodium benzoate+ 2.5% niacinamide) and 
in Blend F7 (10% sodium caprylate +2.5%sodium 
benzoate +2.5% sodium citrate + 2.5% niacinamide) up to 
12.43 % (w/v) that was maximum among all the blends. In 
order to minimize the probable toxic effects of individual 
solubilizer at high concentration, the blends of solubilizers 
were tried to give the expected solubility.  The blends of 
solubilizers of total strength 15% and 17.5% w/v were 
used in selected final blends to get sufficiently expected 
solubilities. The maximum synergistic effect was observed 
in the blend containing sodium caprylate, sodium 
benzoate, niacinamide, sodium acetate, sodium citrate.  
For the development of fast dissolving film, different film 
forming polymers, plasticizers, super disintegrants were 
tested. According to the mechanical properties and 
disintegration time of film, they were selected and 
optimized. HPMC E-5 15% w/v was taken as optimized 
concentration of polymer. On the basis of film properties, 
15% v/v concentration of glycerine (as plasticizer) was 
optimized and selected. Crosspovidone in concentration of 
0.4% w/v was optimized because of desired thickness and 
desired disintegration time (< 30 sec).  
From selected and optimized ingredients, eight batches of 
fast dissolving film containing 20 mg dose of drug per 4 
cm² were developed and evaluated for thickness, folding 
endurance, disintegration time and in-vitro dissolution 
profile. Amongst all the batches, FD5 and FD7 batch of 
prepared fast dissolving films showed better in vitro 
dissolution profile, disintegration time and were selected 
for stability studies. They were found quiet stable for 2 
months.  
CONCLUSION 
From all the above studies, it was concluded that the 
approach of mixed solvency is novel, safe, cost-effective 
and user friendly. It also eliminates the problem of toxicity 
associated with high concentration of single solubilizers. 
So, it may be employed in dosage form development of 
drugs where fast onset of action is desired. It may also 
enhance the bioavailability associated with poor 
dissolution of drug. 
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